This study looks at a medication called orforglipron for people with obstructive sleep apnea (OSA) who are also overweight or have obesity. OSA is when your breathing stops and starts during sleep. The study has two parts: GZ01 for people not using a breathing machine called PAP therapy, and GZ02 for those using it for at least 3 months. The study checks if orforglipron is safe and works well. Participants must have a high Apnea-Hypopnea Index (AHI), which measures sleep apnea, and a Body Mass Index (BMI) of 27 or more. People with certain conditions, like diabetes or other breathing issues, can't join.

• The study has two separate parts: one for people not using PAP therapy and one for those who are.
• Participants must stop other treatments for sleep apnea, except PAP therapy for some.
• People with certain health issues or recent major weight change aren't eligible.